

CONTENTS

PART I: OVERVIEW OF THE COORDINATED RESEARCH PROJECT

CHAPTER 1. OVERVIEW OF THE COORDINATED RESEARCH PROJECT

1.1. Introduction	3
1.1.1. Background	3
1.1.2. Objectives of the coordinated research project	4
1.1.3. Work plan of the coordinated research project	4
1.2. Scientific background on technetium-99m cores	6
1.2.1. [^{99m} Tc(CO) ₃] ⁺ -carbonyl core	6
1.2.1.1. Tridentate chelators	6
1.2.1.2. Combination of bidentate and monodentate chelators (2 + 1 approach)	7
1.2.1.3. Higher technetium-carbonyls	8
1.2.2. [^{99m} Tc≡N] ²⁺ -nitrido core	8
1.2.3. Technetium-99m-HYNIC core	10
1.2.4. ^{99m} Tc(III)/Re(III)-(4 + 1) core	12
1.3. Summary of scientific work	14
1.3.1. Chart 1: Technetium-99m labelling of RGD peptides targeting $\alpha_v\beta_3$ integrin receptors	14
1.3.1.1. Radiolabelling	14
1.3.1.2. Biological characterization	17
1.3.1.3. Conclusion (chart 1)	19
1.3.2. Chart 2: Labelling of annexin V fragments	20
1.3.2.1. Radiolabelling	21
1.3.2.2. Biological characterization	23
1.3.2.3. Conclusion (chart 2)	24
1.3.3. Chart 3: Labelling of fatty acids using the ^{99m} Tc-tricarbonyl core	24
1.3.4. Chart 4: Technetium-99m labelling of quinazoline derivatives	26
1.3.5. Chart 5: Development of technetium-99m glucose analogues	27
1.4. Achievements of the coordinated research project	30
1.5. Intergroup collaborations	31
1.5.1. Exchanges of reagents and precursors	31
1.5.2. Exchange visits	32
1.6. Conclusion	33

PART II: REPORTS BY THE PARTICIPANTS IN THE COORDINATED RESEARCH PROJECT

CHAPTER 2. TECHNETIUM-99m LABELLING OF RGD PEPTIDES TARGETING INTEGRIN RECEPTORS: COMPARISON OF DIFFERENT CONJUGATES OF cRGDyK UTILIZING DIFFERENT TECHNETIUM-99m CORES 37
C. Decristoforo, R. Haubner, M. Rupprich, E. von Guggenberg

2.1. Introduction 38
 2.2. Peptide synthesis and distribution 39
 2.3. Experimental methods 40
 2.3.1. Analytical methods 40
 2.3.1.1. HPLC 40
 2.3.1.2. Purification by solid phase extraction 41
 2.3.2. Technetium-99m labelling 41
 2.3.2.1. HYNIC-cRGDyK 41
 2.3.2.2. Labelling with $[^{99m}\text{Tc}(\text{OH}_2)_3(\text{CO})_3]^+$ 43
 2.3.2.3. 4 + 1 approach 43
 2.3.2.4. Labelling of Cys-RGD with the ^{99m}Tc -nitrido fragment 44
 2.3.3. In vitro evaluation of radiolabelled peptides 44
 2.3.3.1. Stability 44
 2.3.3.2. Protein binding 44
 2.3.3.3. Log *P* values 45
 2.3.4. Internalization and binding studies in $\alpha_v\beta_3$ positive and $\alpha_v\beta_3$ negative cells 45
 2.3.5. In vivo evaluation of radiolabelled peptides 45
 2.4. Results 46
 2.4.1. Characterization of cold peptides 46
 2.4.2. Labelling experiments 46
 2.4.3. Stability experiments, log *P* and protein binding 48
 2.4.4. Internalization studies 48
 2.4.5. In vivo tumour model 50
 2.5. Discussion and outlook 52
 References 52

CHAPTER 3. RADIOLABELLING ANGIOGENIC AND APOPTOTIC AGENT WITH DIFFERENT TECHNETIUM-99m TECHNIQUES 55
B. Linkowski Faintuch, R.L.S. Ribeiro Santos, R. Teodoro, E. Muramoto, L. Morganti, I.V. Da Silva Nunes, M.R.Y. Okamoto

3.1. Introduction 56
 3.1.1. Angiogenesis markers 56
 3.1.2. Investigation of apoptosis 56
 3.1.3. Labelling procedures 57
 3.2. Materials 58
 3.3. Methods 59
 3.3.1. Labelling of HYNIC-RGD and HYNIC-annexin with technetium-99m using EDDA/tricine as exchange products 59
 3.3.2. Preparation of ^{99m}Tc -nitrido precursor 59
 3.3.3. Labelling of Cys-RGD and Cys-annexin using the ^{99m}Tc -nitrido precursor 59
 3.3.4. Radiochemical stability, transchelation towards cysteine and partition coefficient 60
 3.3.5. Synthesis of ^{99m}Tc -carbonyl 60
 3.3.6. Labelling of Ter-Cys-RGD, PZ1-RGD, His-RGD and His-annexin with the precursor $^{99m}\text{Tc}(\text{CO})_3$ 60
 3.3.7. Quality control 60
 3.3.7.1. ^{99m}Tc -HYNIC peptide complexes 60
 3.3.7.2. $^{99m}\text{Tc}(\text{CO})_3$ peptide complexes 61
 3.3.7.3. $^{99m}\text{TcN}(\text{PNP}6)$ peptide complexes 61
 3.3.8. Purification 61
 3.3.9. Biodistribution studies in healthy animals 61
 3.3.10. Animal model with tumour cells 61
 3.3.11. Animal model for annexin studies 62
 3.3.12. Imaging of tumour 62
 3.4. Results and discussion 62
 3.4.1. Labelling of HYNIC-RGD and HYNIC-annexin with technetium-99m using EDDA/tricine as exchange products 62
 3.4.2. Preparation of ^{99m}Tc -nitrido and labelling of Cys-RGD and Cys-annexin 63
 3.4.3. Radiochemical stability, transchelation towards cysteine and partition coefficient 64

3.4.4. Synthesis of ^{99m} Tc-carbonyl and labelling of Ter-Cys-RGD, PZ1-RGD, His-RGD and His-annexin	65
3.4.5. Biodistribution studies in normal and tumour bearing animals	66
3.4.6. Animal model with tumour cells	66
3.4.7. Animal model for annexin studies	69
3.4.8. Imaging of tumour uptake	69
3.5. Conclusions	70
Acknowledgements	72
References	72

CHAPTER 4. RADIOLABELLING OF RGD PEPTIDES USING NOVEL TECHNETIUM-99m CORES

Ji Hu, Baojun Chen, Jixin Liang, Lianzhe Luo, Hongyu Li, Yang Chen, Langtao Shen, Zhifu Luo

4.1. Introduction	75
4.2. Materials and methods	76
4.2.1. Radiolabelling	78
4.2.1.1. Radiolabelling of Cys-RGD with the [^{99m} Tc(N)] ²⁺ core	78
4.2.1.2. Radiolabelling of HYNIC-RGD with ^{99m} Tc	78
4.2.1.3. Radiolabelling of His-RGD and Cys(X)-RGD with [^{99m} Tc(H ₂ O) ₃ (CO) ₃] ⁺	78
4.2.1.4. Purification of radiolabelled RGD peptides	79
4.2.1.5. In vitro stability	79
4.2.2. In vivo animal experiment	79
4.2.2.1. Tumour xenograft	79
4.2.2.2. Biodistribution studies	80
4.2.2.3. Blocking studies	80
4.2.2.4. Gamma camera imaging	80
4.3. Results and discussion	80
4.3.1. Radiolabelling of RGD peptides	80
4.3.1.1. In vitro stability	82
4.3.2. Biodistribution studies	83
4.4. Conclusion	85
References	86

CHAPTER 5. ^{99m}Tc-HYNIC-Anx13: PREPARATION, STABILITY, BIODISTRIBUTION AND IMAGING OF APOPTOSIS

Hongyu Li, Ji Hu, Jixin Liang, Baojun Chen, Ja Lu, Lianzhe Luo, Yang Chen, Zhifu Luo

5.1. Introduction	89
5.2. Materials and methods	90
5.2.1. Radiolabelling of technetium-99m	90
5.2.1.1. Tricine as a coligand	90
5.2.1.2. EDDA as a coligand	90
5.2.1.3. Tricine/EDDA as coligands	90
5.2.2. Quality control	91
5.2.2.1. Thin layer chromatography	91
5.2.2.2. HPLC	91
5.2.2.3. Sep-Pak purification procedure	91
5.2.3. Stability of radiolabelled peptides	92
5.2.4. Biodistribution in normal mice	92
5.2.5. Imaging and biodistribution in apoptotic model animals	92
5.3. Results and discussion	93
5.3.1. Preparation of ^{99m} Tc-tricine-HYNIC-Anx13 using tricine as a coligand	93
5.3.2. Preparation of ^{99m} Tc-EDDA-HYNIC-Anx13 using EDDA as a coligand	93
5.3.3. Technetium-99m labelling of HYNIC-Anx13 using EDDA/tricine as coligands	94
5.3.4. Stability in vivo and in vitro	96
5.3.5. Biodistribution in normal mice	97
5.3.6. Biodistribution and radionuclide imaging in model animals	98
5.4. Conclusion	101
References	101

CHAPTER 6. PREPARATION AND COMPARATIVE EVALUATION OF TECHNETIUM-99m LABELLED FATTY ACIDS

Ji Hu, Jixin Liang, Baojun Chen, Lianzhe Luo, Hongyu Li, Langtao Shen, Zhifu Luo

6.1. Introduction	103
6.2. Materials	104

6.3. Methods	104
6.3.1. Preparation of $[^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ intermediate	104
6.3.2. Labelling of CYST FAC11 and IDA FAC11	105
6.3.3. Purification of radiolabelled products by the SPE method	105
6.3.4. In vitro stability	105
6.3.5. Biodistribution studies in normal mice	106
6.4. Results and discussion	106
6.4.1. Radiolabelling	106
6.4.2. In vitro stability	107
6.4.3. Biodistribution	108
6.5. Conclusions	110
References	112

CHAPTER 7. TECHNETIUM-99m LABELLING OF AN ANNEXIN FRAGMENT USING THE 4 + 1 MIXED LIGAND CHELATE SYSTEM

J.-U. Küntler, B. Pawelke, A. Duatti, J. Környei, H.-J. Pietzsch

7.1. Introduction	113
7.2. Materials and methods	114
7.2.1. General	114
7.2.2. L1-AF, L2-AF, $\text{Re}(\text{NS}_3)(\text{L1-AF})$ and $\text{Re}(\text{NS}_3)(\text{L2-AF})$	114
7.2.3. $^{99m}\text{Tc}(\text{NS}_3)(\text{L1-AF})$ and $^{99m}\text{Tc}(\text{NS}_3)(\text{L2-AF})$	115
7.2.4. In vivo stability	115
7.2.5. Cell binding assay	116
7.2.5.1. Binding studies	116
7.3. Results and discussion	116
7.4. Conclusions	119
References	120

CHAPTER 8. TECHNETIUM-99m LABELLING OF A QUINAZOLINE DERIVATIVE USING THE 4 + 1 MIXED LIGAND CHELATE SYSTEM

J.-U. Küntler, I. Santos, I. Pirmettis, H.-J. Pietzsch

8.1. Introduction	121
8.2. Results and discussion	122
8.2.1. In vitro evaluation	124
8.2.1.1. Inhibition of cell proliferation	124
8.2.1.2. Inhibition of EGFR-TK	126

8.3. Conclusions	126
References	127

CHAPTER 9. TECHNETIUM-99m LABELLING OF THE RGD PEPTIDE c(RGDyK) USING THE 4 + 1 MIXED LIGAND APPROACH

J.-U. Küntler, P. Ansorge, R. Bergmann, E. Gniazdowska, C. Decristoforo, A. Rey, H. Stephan, H.-J. Pietzsch

9.1. Introduction	130
9.2. Materials and methods	130
9.2.1. General	130
9.2.2. L1-c(RGDyK), L2-c(RGDyK), $\text{Re}(\text{NS}_3)(\text{L1-c(RGDyK)})$ and $\text{Re}(\text{NS}_3)(\text{L2-c(RGDyK)})$	131
9.2.3. $\text{Re}(\text{NS}_3(\text{COOH})_3)(\text{L2-c(RGDyK)})$	131
9.2.4. Technetium-99m labelling	132
9.2.5. Analytical data	132
9.2.6. Distribution ratio (log <i>D</i> , octanol/PBS, pH7.4)	132
9.2.7. Biodistribution studies	133
9.3. Results and discussion	133
9.3.1. Biodistribution studies in mice	136
9.4. Conclusions	136
References	140

CHAPTER 10. DEVELOPMENT OF TECHNETIUM-99m LABELLED ANNEXIN V FRAGMENTS USING THE Tc-TRICARBONYL CORE

D. Psimadas, C. Zikos, M. Fani, E. Livaniou, M. Papadopoulos, I. Pirmettis

10.1. Introduction	141
10.2. Materials and methods	141
10.2.1. General	141
10.2.2. Derivatization of CAQVLRGTVTDFPG×2TFA with vinyl pyridine	142
10.2.3. Preparation of the precursor $[^{99m}\text{Tc}(\text{H}_2\text{O})_3(\text{CO})]^+$	142
10.2.4. Radiolabelling of peptides	142
10.2.5. Cysteine and histidine challenge of technetium-99m labelled peptides	143
10.2.6. Biodistribution studies in mice	143

10.3. Results and discussion	143
10.4. Conclusion	145
CHAPTER 11. DEVELOPMENT OF TECHNETIUM-99m	
LABELLED BIOMARKERS FOR HEART	
METABOLISM USING THE Tc-TRICARBONYL	
CORE	
<i>A. Papadopoulos, C. Tsoukalas, A. Panagiotopoulou, M. Pelecanou,</i>	
<i>M. Papadopoulos, I. Pirmettis</i>	
11.1. Introduction	147
11.2. Materials and methods	148
11.2.1. General	148
11.2.2. Synthesis of ligands	148
11.2.2.1. Synthesis of 11-[bis(carboxymethyl)amino]	
undecanoic acid (IDA-FA11)	148
11.2.2.2. Synthesis of 11-(S-cysteine)undecanoic acid	
Cyst-FA11	149
11.2.2.3. Synthesis of 16-(S-cysteine)hexadecanoic acid	
Cyst-FA16	149
11.2.2.4. Synthesis of 16-(S-cysteine)hexadecanoic acid	
dimethylester, Cyst-FA16 dimethylester	150
11.2.2.5. Synthesis of N-undecanoicdithiocarbamate	
sodium salt CS2-FA11	150
11.2.2.6. Synthesis of 16-(N-(pyridine-2-yl-methyl)-N-	
aminoethyl acetate)hexadecanoic ethylester	
PAM-FA16	150
11.2.2.7. Synthesis of NSC-FA11	150
11.2.3. Synthesis of rhenium complexes	151
11.2.3.1. Synthesis of $\text{Re}(\text{CO})_3(\text{IDA-FA11})$	151
11.2.3.2. Synthesis of the complex $\text{Re}(\text{CO})_3(\text{Cyst-FA11})$	151
11.2.3.3. Synthesis of the complex $\text{Re}(\text{CO})_3(\text{NSC-FA11})$	152
11.2.3.4. Synthesis of the complex $\text{Re}(\text{CO})_3\text{PAM-FA16}$	152
11.2.4. Labelling with technetium-99m	152
11.2.4.1. Preparation of the precursor	
$[\text{}^{99\text{m}}\text{Tc}(\text{H}_2\text{O})_3(\text{CO})]^+$	152
11.2.4.2. General method for the preparation of	
the technetium-99m labelled fatty acids with	
$[\text{}^{99\text{m}}\text{Tc}(\text{CO})_3]^+$	153
11.2.4.3. Synthesis of the technetium-99m complex with	
11-[bis(carboxymethyl)amino]undecanoic acid	153

11.2.4.4. Synthesis of the complex $[\text{}^{99\text{m}}\text{Tc}(\text{CO})_3$	
(Cyst-FA11)	153
11.2.4.5. Synthesis of the complex $[\text{}^{99\text{m}}\text{Tc}(\text{CO})_3$	
(NSC-FA11)	153
11.3. Results and discussion	156
11.4. Conclusions	156
References	156
CHAPTER 12. DEVELOPMENT OF TECHNETIUM-99m	
LABELLED BIOMARKERS FOR EGFR-TK	
USING THE Tc-TRICARBONYL CORE	
<i>N. Margaritis, N. Bourkoula, M. Paravatou, E. Livaniou,</i>	
<i>A. Papadopoulos, A. Panagiotopoulou, C. Tsoukalas,</i>	
<i>M. Pelecanou, M. Papadopoulos, I. Pirmettis</i>	
12.1. Introduction	157
12.2. Materials and methods	158
12.2.1. General	158
12.2.2. Synthesis	158
12.2.2.1. 6-nitroquinazoline (1)	158
12.2.2.2. 4-chloro-6-nitroquinazoline (2)	159
12.2.2.3. 4-[(3-bromophenyl)amino]-6-nitro-	
quinazoline (3)	159
12.2.2.4. 6-amino-4-[(3-bromophenyl)amino]-	
quinazoline (4)	159
12.2.2.5. 6-(pyridine-2-methylimin)-4-[(3-bromophenyl)	
amino]-quinazoline (5)	160
12.2.2.6. N-{4-[(3-bromophenyl)amino]-quinazoline-6-yl}-	
2-chloroacetamide (6)	160
12.2.3. Synthesis of rhenium complexes, general method	160
12.2.4. Labelling with technetium-99m	161
12.2.4.1. Preparation of the precursor	
$[\text{}^{99\text{m}}\text{Tc}(\text{H}_2\text{O})_3(\text{CO})]^+$	161
12.2.4.2. General method for the preparation of the $^{99\text{m}}\text{Tc}$	
labelled quinazolines $[\text{}^{99\text{m}}\text{Tc}(\text{CO})_3]^+$	161
12.2.4.3. In vitro evaluation of quinazoline analogues	161
12.3. Results and discussion	162
12.4. Conclusions	164
References	164

CHAPTER 13. DEVELOPMENT OF ANNEXIN V FRAGMENTS
FOR LABELLING WITH TECHNETIUM-99m 167

J. Környei, F. Tóth, E. Szemenyei, A. Duatti

13.1. Introduction	167
13.2. Materials and methods	168
13.2.1. Synthesis of annexin V fragments	168
13.2.2. Stability studies	168
13.2.3. ^{99m} Tc-nitrido labelling	169
13.2.4. Determination of the radiochemical purity	169
13.3. Results and discussion	169
13.3.1. Peptide synthesis and stability	169
13.3.2. ^{99m} Tc-nitrido labelling	172
13.3.3. Other studies with derivatized Anx13 fragments	174
13.4. Conclusions	175
References	175

CHAPTER 14. DEVELOPMENT OF TECHNETIUM-99m
BASED SMALL BIOMOLECULES USING
NOVEL TECHNETIUM-99m CORES:
^{99m}Tc-TRICARBONYL, ^{99m}Tc-HYNIC AND
^{99m}Tc-NITRIDO CHEMICAL APPROACHES 177

*K. Kothari, A. Mukherjee, D. Satpati, A. Korde, S. Joshi,
H.D. Sarma, A. Mathur, M. Mallia, S. Banerjee, M. Venkatesh*

14.1. Introduction	178
14.2. Materials	180
14.3. Methods	181
14.3.1. Synthesis and characterization of ^{99m} Tc(CO) ₃ -RGD, ^{99m} Tc(N)-RGD and ^{99m} Tc-HYNIC-RGD complexes	181
14.3.1.1. Synthesis of ^{99m} Tc-tricarbonyl complexes of RGD	181
14.3.1.2. Preparation of ^{99m} Tc-nitrido complexes of RGD ...	182
14.3.1.3. Synthesis of ^{99m} Tc-HYNIC-RGD	182
14.3.1.4. Quality control	183
14.3.1.5. In vitro studies	183
14.3.1.6. In vivo studies	184
14.3.2. Synthesis and evaluation of ^{99m} Tc(N)-Anx13 and ^{99m} Tc(CO) ₃ -Anx13 as apoptosis marker	184

14.3.2.1. Preparation and characterization of technetium-99m Anx13	185
14.3.2.2. In vitro studies	185
14.3.2.3. In vivo studies	186
14.3.3. Synthesis and characterization of technetium-99m fatty acid analogues for myocardial imaging	187
14.3.3.1. Radiolabelling studies	187
14.3.3.2. Quality control	188
14.3.3.3. In vitro studies	188
14.3.3.4. In vivo studies	188
14.4. Results	189
14.4.1. Synthesis and characterization of ^{99m} Tc(CO) ₃ -RGD and ^{99m} Tc(N)-RGD for tumour targeting	189
14.4.1.1. ^{99m} Tc-tricarbonyl complexes of RGD	189
14.4.1.2. ^{99m} Tc(N)Cys-RGD (symmetric complexes)	189
14.4.1.3. ^{99m} Tc(N)(PNP)-Cys-RGD (asymmetric complex)	190
14.4.1.4. Preparation of ^{99m} Tc-HYNIC-RGD	190
14.4.1.5. In vitro studies	190
14.4.1.6. In vivo studies	191
14.4.2. Synthesis and evaluation of ^{99m} Tc(N)-Anx13 and ^{99m} Tc(CO) ₃ -Anx13 as an apoptosis marker	191
14.4.2.1. Radiolabelling of Anx13 analogues	191
14.4.2.2. In vitro studies	192
14.4.2.3. In vivo studies	195
14.4.3. Synthesis and characterization of ^{99m} Tc(CO) ₃ undeconic acid for myocardial imaging	197
14.4.3.1. ^{99m} Tc(CO) ₃ -CYSFA11	197
14.4.3.2. ^{99m} Tc(CO) ₃ -CYSFA16	198
14.4.3.3. ^{99m} Tc(N)-CS2FA11	198
14.5. Conclusion	200
Acknowledgements	200
References	201

CHAPTER 15. LABELLING OF SMALL MOLECULES
WITH THE ^{99m}Tc-NITRIDO CORE 203

M. Pasquali, L. Uccelli, A. Boschi, A. Duatti

15.1. Introduction	203
15.2. Labelling methods	204
15.2.1. Symmetrical complexes	204

15.2.2. Asymmetrical complexes	204
15.3. Results and discussion	206
15.3.1. Development of ^{99m}Tc glucose analogues	206
15.3.2. Labelling of bioactive peptides	207
15.3.2.1. RGD peptides	208
15.3.2.2. Annexin V	210
15.3.2.3. Quinazoline ligands	211
15.4. Experimental procedures	215
15.4.1. Symmetrical complexes	215
15.4.1.1. Bis(dithiocarbamate) nitrido ^{99m}Tc complexes	215
15.4.2. Asymmetrical complexes	215
15.4.2.1. Mixed $[\text{}^{99m}\text{Tc}(\text{N})(\text{PNP})(\text{XY})]^{0/+}$ (PNP = amino- bis-phosphino ligand; XY = monoanionic or dianionic bidentate ligand) complexes	215
15.4.2.2. Mixed $[\text{}^{99m}\text{Tc}(\text{N})(\text{PS})(\text{DTC})]$ (PS = phosphino-thiol ligand; DTC = monoanionic dithiocarbamate ligand) complexes	217
References	218

CHAPTER 16. LABELLING OF QUINAZOLINE AND RGD PEPTIDES WITH THE $[\text{}^{99m}\text{Tc}(\text{CO})_3]^+$ CORE: SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL EVALUATION

<i>I. Santos, C. Fernandes, S. Alves, J. Galamba, L. Gano, I. Pirmettis, C. Decristoforo, C.J. Smith, R. Alberto</i>	219
16.1. Introduction	220
16.2. Results	221
16.2.1. Synthesis and characterization of quinazoline derivatives to be coupled to different chelators and synthesis of a novel chelator for tricarbonyl	221
16.2.2. Evaluation of L^1 as a new ligand for the $[\text{}^{99m}\text{Tc}(\text{CO})_3]^+$ core	222
16.2.3. Conjugation of a quinazoline fragment to L^1 and labelling of the conjugate with the $[\text{}^{99m}\text{Tc}(\text{CO})_3]^+$ core	223
16.2.4. Cell growth and EGFR-TK inhibition	225
16.2.5. Labelling of an RGD peptide with the <i>fac</i> - $[\text{}^{99m}\text{Tc}(\text{CO})_3]^+$ moiety	227
16.2.6. Internalization and binding studies in $\alpha_v\beta_3$ positive and $\alpha_v\beta_3$ negative cells	227
16.2.7. Biodistribution in healthy and in nu/nu mice	228

16.3. Summary and conclusions	229
References	230

CHAPTER 17. LIGANDS OF LOW DENTICITY AS COORDINATION UNITS FOR TETHERING THE ^{99m}Tc -CARBONYL CORE TO BIOMOLECULES

<i>N.I. Gorshkov, E.M. Levitskaya, A.A. Lumpov, A.E. Miroslavov, G.V. Sidorenko, D.N. Suglobov</i>	233
17.1. Introduction	233
17.2. Experimental	234
17.3. 2 + 1 ligand systems for binding Tc-tricarbonyl core	235
17.3.1. Complexation with bidentate ligands	235
17.3.2. 2 + 1 systems with dithiocarbamates	236
17.3.3. 2 + 1 systems with bidentate nitrogen bases	237
17.3.4. Biodistribution studies of 2 + 1 systems with bipyridine and related compounds	238
17.4. Derivatives of higher technetium-carbonyls	240
17.4.1. Preparation of higher technetium-carbonyls at the non-carrier added level	241
17.4.2. Tetracarbonyltechnetium diethyldithiocarbamate	243
17.4.3. Pentacarbonyltechnetium phosphine and isonitrile complexes	243
17.4.4. Hexacarbonyltechnetium(I) cation	244
17.5. Conclusion	247
Acknowledgements	247
References	247

CHAPTER 18. SMALL MOLECULE LABELLING WITH $[\text{}^{99m}\text{Tc}(\text{OH}_2)_3(\text{CO})_3]^+$: LIGANDS, AMINO ACIDS AND INTERCALATORS

<i>R. Alberto, Y. Liu, N. Agorastos, I. Santos, P. Raposinho, H. Knight, J. Mertens, M. Bauwens</i>	249
18.1. Introduction	250
18.2. Results	251
18.2.1. New ligands for the $[\text{Tc}(\text{CO})_3]^+$ core	251
18.2.2. Labelling of amino acids	252
18.2.3. Targeting the nucleus: intercalators	254
18.2.4. Kit preparation of $[\text{}^{188/186}\text{Re}(\text{OH}_2)_3(\text{CO})_3]^+$	256
18.3. Summary and conclusions	257

18.4. Experimental	258
18.4.1. Triethyl 1,6-diacetamido-6-cyano-hexane-1,1,6-tricarboxylate (II)	258
18.4.2. Triethyl 1,6-diacetamido-7-(tert-butoxycarbonylamino)heptane-1,1,6-tricarboxylate (III)	259
18.4.3. Preparation of V	259
Acknowledgements	260
References	260

CHAPTER 19. DESIGN AND EVALUATION OF POTENTIAL ^{99m}Tc RADIOPHARMACEUTICALS BASED ON THE Tc-CARBONYL, 4 + 1 MIXED LIGAND CHELATE SYSTEM AND Tc-NITRIDO APPROACHES

J. Giglio, A. Muslera, M. Incerti, R. Fernández, E. León, A. Paolino, A. Brugnini, E. Manta, A. Chabalgoity, A. León, A. Rey

19.1. Introduction	262
19.2. Materials	263
19.3. Methods	263
19.3.1. Synthesis of glucose derivatives	263
19.3.1.1. N-(3,4,6-tri-O-acetyl-β-D-glucopyranosyl)piperidine (1)	263
19.3.1.2. N-[3,4,6-tri-O-acetyl-2-O-(6-bromohexyl)β-D-glucopyranosyl]piperidine (2)	264
19.3.1.3. N-[3,4,6-tri-O-acetyl-2-O-(6-bromobutyl)β-D-glucopyranosyl]piperidine (2')	264
19.3.1.4. (2R,3S,4R,5R)-2-(acetoxymethyl)-5-(4-azidobutyl)-6-(piperidin-1-yl)-tetrahydro-2H-pyran-3,4-diyl diacetate (3)	265
19.3.1.5. (2R,3S,4R,5R)-2-(acetoxymethyl)-5-(4-azidobutyl)-6-(piperidin-1-yl)-tetrahydro-2H-pyran-3,4-diyl diacetate (4)	265
19.3.1.6. (2-aminoethylamino)acetic acid (5)	265
19.3.2. Preparation and evaluation of technetium-99m labelled RGD peptides	266
19.3.2.1. Technetium-99m labelling	266
19.3.2.2. In vitro evaluation	267
19.3.2.3. in vivo evaluation	268

19.3.3. Preparation and evaluation of technetium-99m labelled annexin 13 peptides	268
19.3.3.1. Biodistribution in animals treated with doxorubicin	269
19.4. Results and discussion	269
19.4.1. Glucose derivatives	270
19.4.2. RGD peptides	271
19.4.2.1. Labelling of RGD peptides with HYNIC	271
19.4.2.2. Labelling of RGD peptides with tricarbonyl	274
19.4.2.3. Labelling of RGD peptides with 4 + 1 chemistry	277
19.4.2.4. Labelling of RGD peptides with nitrido chemistry	279
19.4.3. Annexin	280
19.4.3.1. Labelling of annexin peptides with HYNIC and carbonyl	281
19.5. Conclusions	284
Acknowledgements	284
References	284

CHAPTER 20. IN VITRO AND IN VIVO EVALUATION OF [^{99m}Tc(CO)₃-CYCLO[Arg-Gly-Asp-D-Tyr-Lys(PZ1)]]

S. Alves, J.D.G. Correia, I. Santos, C. Decristoforo, R. Alberto, C.J. Smith

20.1. Introduction	287
20.2. Materials	290
20.3. Methods	290
20.3.1. Synthesis of PZ1 (3,5Me ₂ -PZ(CH ₂) ₂ N((CH ₂) ₃ COOH)(CH ₂) ₂ NH-BOC)	290
20.3.2. Peptide synthesis	291
20.3.3. Radiolabelling of PZ1-RGD conjugate cyclo[Arg-Gly-Asp-D-Tyr-Lys(PZ1)]	292
20.3.4. In vitro serum stability	292
20.3.5. In vitro internalization analysis	292
20.3.6. In vivo evaluation of [^{99m} Tc(CO) ₃ -cyclo[Arg-Gly-Asp-D-Tyr-Lys(PZ1)]] in normal mouse models	293
20.4. Results	294
20.5. Conclusion	300
References	301

